Vnitr Lek 2013, 59(7):624-626

Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia

H. Klamová
Ústav hematologie a krevní transfuze Praha, ředitel prof. MUDr. Marek Trněný, CSc.

Chronic myeloid leukaemia (CML) is an example of a tumour disease, in which the discovery of its molecular principle resulted in the development of the specific targeted molecular treatment with the first representative being imatinib. The introduction of other tyrosine kinase inhibitors, nilotinib and dasatinib, into the clinical practice meant not only a revolutionary change in the treatment approach to CML but literally an epochal improvement of the prognosis and quality of life. The disease with an originally fatal prognosis in patients diagnosed in the chronic stage has changed into a disease with the expected survival rate median estimated to be more than 25 years.

Keywords: chronic myeloid leukaemia; tyrosine kinase inhibitors; imatinib; dasatinib; nilotinib

Received: May 1, 2013; Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Klamová H. Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia. Vnitr Lek. 2013;59(7):624-626.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370: 342-350. Go to original source... Go to PubMed...
    2. Rohrbacher M, Berger U, Hochhaus SA et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009; 23: 602-604. Go to original source... Go to PubMed...
    3. Faderl S, Talpaz M, Estrov Z et al. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219. Go to original source... Go to PubMed...
    4. Kantarjian HM, O'Brien S, Cortes JE et al. Complete cytogenetic and molecular response to interferon-alfa-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033-1041. Go to original source... Go to PubMed...
    5. Drucker BJ, Tamura S, Buchdunger E et al. Effect of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566. Go to original source... Go to PubMed...
    6. Hochhaus A, O'Brien SG, Guilhot F et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054-1061. Go to original source... Go to PubMed...
    7. Goldman JM. Treatment strategies for CML. In: Rowe JM, Hehlman R (eds). Best Practice & Research. Clinical Haematology 2009; 22: 303-313. Go to original source...
    8. Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007; 109: 2303-2309. Go to original source... Go to PubMed...
    9. Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007; 110: 3540-3546. Go to original source... Go to PubMed...
    10. Cortes JE, Kantarjian HM, Brümmendorf TH et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase chronic Ph+ CML patients with resistance or intolerance to imatinib. Blood 2011; 118: 4567-4576. Go to original source... Go to PubMed...
    11. Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657-662. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.